SYGNIS AG announces global launch of CovCheckTM kit for quality control of the whole genome amplification process
? SYGNIS continues to execute its product launch program 2016
? CovCheckTM ready to use quality control tool for the whole genome amplification
(WGA) coverage to determine the quality and integrity of the amplified DNA
? No other product available is able to assess all human chromosomes in a single
experiment
Madrid, Spain, and Heidelberg, Germany – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of CovCheckTM, a ready to use quality control tool for whole genome amplification (WGA) coverage to determine the quality and integrity of the amplified DNA. The end point PCR based kit, which includes 24 different sets of primer pairs each targeting a specific human chromosome, enables the evaluation of the genomic coverage of four independent single-cell whole genome amplification experiments simultaneously.
CovCheckTM is an end point PCR based kit in a convenient 96-well plate format. No other product available is able to as